Darktrace: What we learned from building a £2.5bn UK success story

Mike Lynch writes for City A.M. on what he learnt taking Darktrace from a clever idea on a Cambridge whiteboard to a multi-billion-pound IPO on the London Stock Exchange. Dr Lynch and the Invoke team were instrumental in creating the vision behind Darktrace’s Enterprise Immune System technology and finding the right team to scale the business into the success it has become today.

You can read the full piece here.